Heparin Ratiopharm

Heparin Ratiopharm is a medicinal product that contains the active ingredient heparin sodium. It is supplied in an injectable form for subcutaneous administration, and it is marketed in the European Union. The preparation is classified as an anticoagulant and is used to reduce the risk of blood clot formation in clinical settings. It belongs to the antithrombotic therapeutic class and follows the ATC code B01AB01.

Heparin Ratiopharm is indicated for the prevention and treatment of thromboembolic disorders where anticoagulation is required.

- Prevention of deep‑vein thrombosis (DVT) following surgery or prolonged immobilisation. - Prophylaxis of pulmonary embolism in at‑risk patients. - Treatment of acute coronary syndromes, including unstable angina. - Management of clotting in patients undergoing haemodialysis or extracorporeal circuits. - Adjunct therapy during cardiac surgery to maintain anticoagulation.

The safety profile of Heparin Ratiopharm reflects the typical effects observed with heparin sodium administered subcutaneously.

Common: - Minor bruising or bleeding at the injection site. - Small haematomas or superficial skin erythema. - Transient elevation of liver enzymes. - Mild nausea or headache.

Serious: - Heparin‑induced thrombocytopenia (HIT) with a rapid drop in platelet count. - Major bleeding events such as gastrointestinal or intracranial haemorrhage. - Allergic reactions ranging from urticaria to anaphylaxis.

When prescribing Heparin Ratiopharm, clinicians should consider several precautionary measures to minimise risk.

- Assess baseline coagulation parameters and platelet count before initiating therapy. - Adjust dose in patients with renal impairment or those receiving concurrent anticoagulants. - Monitor for signs of bleeding, especially in the gastrointestinal or central nervous system. - Avoid use in individuals with a known history of heparin‑induced thrombocytopenia. - Use caution during pregnancy and lactation; evaluate risk‑benefit ratio. - Re‑evaluate therapy regularly in elderly patients or those with hepatic dysfunction.

Heparin sodium may interact with a range of medications, influencing its anticoagulant effect.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) that markedly increase bleeding risk. - Antiplatelet agents such as aspirin, clopidogrel, or non‑steroidal anti‑inflammatory drugs (NSAIDs). - Thrombolytic drugs (e.g., alteplase, streptokinase).

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) at low doses, requiring close monitoring of bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents that may impair platelet function. - High‑dose corticosteroids, which can potentiate anticoagulant effects.